Cel-Sci Corp. (CVM) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Cel-Sci is focused on improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. The company’s lead investigational therapy is Multikine, currently being studied in a pivotal global phase 3 clinical trial. CVM is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients, and a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. For more information visit the company’s Web site at www.cel-sci.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
